.jpg?format=webp&width=780)
Gilead's Veklury (remdesivir) gains FDA approval for COVID-19 treatment in individuals with liver disease. The supplemental application covers mild to severe hepatic impairment, extending Veklury's antiviral scope. This marks a milestone as the sole approved COVID-19 antiviral for all liver disease stages. The decision is based on a Phase I study indicating safe pharmacokinetics in hepatic impairment patients without new safety concerns. Despite recommendations for initial hepatic testing, no dose adjustments are now necessary.
Like
Save
Share